BACKGROUND AND OBJECTIVES: Double-chamber peritoneal dialysis fluids exert less toxicity by their neutral pH and reduced glucose degradation product content. The role of the buffer compound (lactate and bicarbonate) has not been defined in humans. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A multicenter randomized controlled trial in 37 children on automated peritoneal dialysis was performed. After a 2-month run-in period with conventional peritoneal dialysis fluids, patients were randomized to neutral-pH, low-glucose degradation product peritoneal dialysis fluids with 35 mM lactate or 34 mM bicarbonate content. Clinical and biochemical monitoring was performed monthly, and peritoneal equilibration tests and 24-hour clearance studies were performed at 0, 3, 6, and 10 months. RESULTS: No statistically significant difference in capillary blood pH, serum bicarbonate, or oral buffer supplementation emerged during the study. At baseline, peritoneal solute equilibration and clearance rates were similar. During the study, 4-hour dialysis to plasma ratio of creatinine tended to increase, and 24-hour dialytic creatinine and phosphate clearance increased with lactate peritoneal dialysis fluid but not with bicarbonate peritoneal dialysis fluid. Daily net ultrafiltration, which was similar at baseline (lactate fluid=5.4±2.6 ml/g glucose exposure, bicarbonate fluid=4.9±1.9 ml/g glucose exposure), decreased to 4.6±1.0 ml/g glucose exposure in the lactate peritoneal dialysis fluid group, whereas it increased to 5.1±1.7 ml/g glucose exposure in the bicarbonate content peritoneal dialysis fluid group (P=0.006 for interaction). CONCLUSIONS: When using biocompatible peritoneal dialysis fluids, equally good acidosis control is achieved with lactate and bicarbonate buffers. Improved long-term preservation of peritoneal membrane function may, however, be achieved with bicarbonate-based peritoneal dialysis fluids.
RCT Entities:
BACKGROUND AND OBJECTIVES: Double-chamber peritoneal dialysis fluids exert less toxicity by their neutral pH and reduced glucose degradation product content. The role of the buffer compound (lactate and bicarbonate) has not been defined in humans. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A multicenter randomized controlled trial in 37 children on automated peritoneal dialysis was performed. After a 2-month run-in period with conventional peritoneal dialysis fluids, patients were randomized to neutral-pH, low-glucose degradation product peritoneal dialysis fluids with 35 mM lactate or 34 mM bicarbonate content. Clinical and biochemical monitoring was performed monthly, and peritoneal equilibration tests and 24-hour clearance studies were performed at 0, 3, 6, and 10 months. RESULTS: No statistically significant difference in capillary blood pH, serum bicarbonate, or oral buffer supplementation emerged during the study. At baseline, peritoneal solute equilibration and clearance rates were similar. During the study, 4-hour dialysis to plasma ratio of creatinine tended to increase, and 24-hour dialytic creatinine and phosphate clearance increased with lactate peritoneal dialysis fluid but not with bicarbonate peritoneal dialysis fluid. Daily net ultrafiltration, which was similar at baseline (lactate fluid=5.4±2.6 ml/g glucose exposure, bicarbonate fluid=4.9±1.9 ml/g glucose exposure), decreased to 4.6±1.0 ml/g glucose exposure in the lactate peritoneal dialysis fluid group, whereas it increased to 5.1±1.7 ml/g glucose exposure in the bicarbonate content peritoneal dialysis fluid group (P=0.006 for interaction). CONCLUSIONS: When using biocompatible peritoneal dialysis fluids, equally good acidosis control is achieved with lactate and bicarbonate buffers. Improved long-term preservation of peritoneal membrane function may, however, be achieved with bicarbonate-based peritoneal dialysis fluids.
Authors: Martin Zeier; Vedat Schwenger; Reinhold Deppisch; Ulrike Haug; Kai Weigel; U Bahner; Christoph Wanner; H Schneider; Thomas Henle; Eberhard Ritz Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: Liesbeth H P Hekking; Mohammad Zareie; Bas A J Driesprong; Dirk Faict; Angelique G A Welten; Inge de Greeuw; Inge L Schadee-Eestermans; Carin E G Havenith; Jacob van den Born; Piet M Ter Wee; Robert H J Beelen Journal: J Am Soc Nephrol Date: 2001-12 Impact factor: 10.121
Authors: J Plum; P Razeghi; R M Lordnejad; A Perniok; M Fleisch; A Fusshöller; M Schneider; B Grabensee Journal: Am J Kidney Dis Date: 2001-10 Impact factor: 8.860
Authors: Susanne Haas; Claus Peter Schmitt; Klaus Arbeiter; Klaus-Eugen Bonzel; Michel Fischbach; Ulrike John; Anne-Kathrin Pieper; Thomas Patrick Schaub; Jutta Passlick-Deetjen; Otto Mehls; Franz Schaefer Journal: J Am Soc Nephrol Date: 2003-10 Impact factor: 10.121
Authors: Katarzyna Wieczorowska-Tobis; Renata Brelinska; Janusz Witowski; Jutta Passlick-Deetjen; Thomas P Schaub; Holger Schilling; Andrzej Breborowicz Journal: Perit Dial Int Date: 2004 Jan-Feb Impact factor: 1.756
Authors: Janusz Witowski; Katarzyna Korybalska; Krzysztof Ksiazek; Justyna Wisniewska-Elnur; Achim Jörres; Cristina Lage; Thomas P Schaub; Jutta Passlick-Deetjen; Andrzej Breborowicz; Alicja Grzegorzewska; Andrzej Ksiazek; Tomasz Liberek; Monika Lichodziejewska-Niemierko; Maria Majdan; Boleslaw Rutkowski; Tomasz Stompór; Wladyslaw Sulowicz Journal: Nephrol Dial Transplant Date: 2004-04 Impact factor: 5.992
Authors: Gwendolyn Eich; Maria Bartosova; Christian Tischer; Tanja Tamara Wlodkowski; Betti Schaefer; Sebastian Pichl; Nicole Kraewer; Bruno Ranchin; Karel Vondrak; Max Christoph Liebau; Thilo Hackert; Claus Peter Schmitt Journal: PLoS One Date: 2017-12-18 Impact factor: 3.240
Authors: Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho Journal: Cochrane Database Syst Rev Date: 2018-10-26
Authors: Allison Tong; Susan Samuel; Michael Zappitelli; Allison Dart; Susan Furth; Allison Eddy; Jaap Groothoff; Nicholas J A Webb; Hui-Kim Yap; Detlef Bockenhauer; Aditi Sinha; Stephen I Alexander; Stuart L Goldstein; Debbie S Gipson; Camilla S Hanson; Nicole Evangelidis; Sally Crowe; Tess Harris; Brenda R Hemmelgarn; Braden Manns; John Gill; Peter Tugwell; Wim Van Biesen; David C Wheeler; Wolfgang C Winkelmayer; Jonathan C Craig Journal: Trials Date: 2016-08-12 Impact factor: 2.279